Hanall Biopharma’s Slide: A Symptom of a Broader Pharmaceutical Malaise

Hanall Biopharma (009420.KS) has slipped 0.25 % over the past 24 hours, closing at KRW 38,550 as of 11:44 AM Central Europe on Monday, 26 th. The stock’s current supply sits at 50.7 million shares, and its market cap hovers around KRW 2 trillion—a figure that belies the company’s waning momentum. In the last 24 hours, investors exchanged a mere KRW 9.3 billion of shares, a stark contrast to the KRW 51,867.25 simple moving average over the last 200 days. The 52‑week high—KRW 73,000 on 27 May 2026—remains a distant memory, while the low of KRW 33,450 on 30 October 2025 underscores the stock’s volatile nature.

The decline is not an isolated phenomenon. Since the end of last month, Hanall has fallen 7.37 %, signaling a systemic erosion of confidence among investors. In the broader Korean market, the company’s peers are painting a more nuanced picture:

  • Nongshim (004370.KS) has gained 0.75 %, now trading at KRW 393,000 with a market cap of KRW 2.4 trillion and a P/E of 11.99.
  • Fadu (440110.KQ) has dropped 4.28 %, trading at KRW 44,800 and a market cap of KRW 2.4 trillion.
  • F&f /New (383220.KS) slipped 2.48 %, trading at KRW 60,200, also with a KRW 2.4 trillion market cap and a P/E of 4.97.
  • Voronoi (310210.KQ) remains flat at 0 %, trading at KRW 122,300 with a market cap of KRW 2.4 trillion.

While the Korean market displays a mix of gains and losses, Hanall’s persistent slide raises questions about the company’s strategic direction and product pipeline. Founded in 1973 and headquartered in Seoul, Hanall has long positioned itself as a research‑driven biopharmaceutical firm. Its portfolio includes:

  • HL161, an anti‑FcRn antibody aimed at autoimmune diseases.
  • HL036, an anti‑TNF bio‑ophthalmic solution for dry eye disease.
  • HL186 / HL187, targeting recurrent or intractable cancers.
  • HL040 and HL068 for hypertension and dyslipidemia.
  • HL018 for obesity.
  • IM156 for oncology.

Despite this breadth, the company’s performance suggests that the translation from research to revenue is faltering. The market cap of KRW 2 trillion is underpinned by a stock price that has never breached its 52‑week high for nearly a year, and the simple moving average indicates a sustained downtrend that is difficult to ignore.

Investors looking for a quick rebound may find themselves disappointed. The data speak plainly: Hanall’s stock is under pressure, and the company’s ambitious pipeline has yet to deliver the commercial success required to justify its valuation. The future of Hanall Biopharma hinges on whether the firm can convert its research potential into tangible market gains—a challenge that, as of now, remains unproven.